



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,523	11/21/2003	Kenneth J. Rothschild	AMBER-08501	3365
<div>7590 MEDLEN &amp; CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, CA 94105</div>				
<div>11/13/2008</div>				
EXAMINER				
JOIKE, MICHELE K				
ART UNIT		PAPER NUMBER		
1636				
MAIL DATE		DELIVERY MODE		
11/13/2008		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

**Application No.**

10/719,523

**Applicant(s)**

ROTHSCHILD ET AL.

**Examiner**

MICHELE K. JOIKE

**Art Unit**

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 31 July 2008.  
2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.  
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1, 9 and 11-13 is/are pending in the application.  
4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.  
6) ☒ Claim(s) 1, 9, 11-13 is/are rejected.  
7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.  
8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.  
10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)  
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)  
3) ☐ Information Disclosure Statement(s) (PTO/5508)  
Paper No(s)/Mail Date \_\_\_\_\_  
4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_  
5) ☐ Notice of Informal Patent Application  
6) ☐ Other: \_\_\_\_\_

### **DETAILED ACTION**

Receipt is acknowledged of a reply to the previous Office Action, filed July 31, 2008. Claims 1, 9 and 11-13 are pending and examined.

Any rejection of record in the previous Office Action, mailed March 20, 2008 that is not addressed in this action has been withdrawn.

Because this Office Action only maintains rejections set forth in the previous Office Action and/or sets forth new rejections that are necessitated by amendment, this Office Action is made FINAL.

#### ***Response to Arguments Concerning Claim Rejections – 35 USC § 103 (a)***

Applicants' arguments filed March 20, 2008 have been fully considered but they are not persuasive.

The following grounds of traversal are presented:

Both Little and Garvin simply teach that protein mass can be determined by mass spec., which is an irrelevant similarity that leads to hindsight-driven combination.

These arguments are not found persuasive for the following reasons.

Together, Little and Garvin teach the limitations as discussed below in a new 35 USC 103(a) rejection. The references, and the motivation to combine them, also are discussed below. The new rejection is made in response to Applicants' amendments.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 9 and 11-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Little et al (US Patent No. 6,207,370) in view of Garvin et al (US Patent No. 6,329,180; IDS Ref. 1) and in further view of Knop et al.

Little et al teach a reaction mixture for amplifying a nucleic acid as a means of detecting and isolated a mutation in a genetic region, the reaction mixture comprising

a) a first oligonucleotide primer comprising i) a T7 promoter sequence, ii) a ribosome binding site sequence, iii) a start codon, iv) a sequence coding for a first epitope marker and v) a first region of complementarity to a region of the APC gene; and

b) a second oligonucleotide primer comprising i) at least one stop codon, and ii) a sequence encoding for a second epitope marker,

wherein said first epitope marker is SEQ ID NO: 5, a hexahistidine tag (see entire document, especially column 3, lines 10-21 and 50-58; column 4, lines 20-22; column 9, lines 38-49; column 14, lines 1-3, 31-38, 51-55; column 15, lines 19-29).

Little et al also teach the use of other tags for use in their method including a 10-residue sequence from c-myc, the pFLAG system, and a 16 amino acid portion of the *Haemophilus influenza* hemagglutinin protein (see column 14, lines 45-58). The

primers taught by Little et al can be used to amplify target genes which are not limited to APC, but include, e.g., BRCA1, BRCA2, dystrophin gene, CFTR, etc. (see column 4, lines 10-25). Little et al also teach that in one embodiment, an RNA molecule encoding a target polypeptide can be translated in a cell-free extract, such as a reticulocyte lysate, a wheat germ extract, or a combination thereof (see column 3, lines 28-32). Finally, Little et al teach that the primer used in the reaction "typically contains 15-25 nucleotides" but may be longer or shorter depending on many factors, including temperature and source of primer and use of the method (see column 13, lines 35-44). Little et al also teach the use of mass spectrometry to determine the mass/identification of the translated protein (see, e.g., column 3, lines 50-59 and column 26, lines 30-39).

Little et al do not explicitly teach this method wherein the first and second epitope markers are different and wherein the second epitope marker is selected from the group consisting of SEQ ID NOS: 6-9, nor do they teach use of two epitope markers for the first primer.

Garvin et al teach a kit and methods for detecting protein altering mutations in genes such as BRCA1 and BRCA2 (see entire document, including the Abstract and column 1, lines 21-36). The method comprises the use of a 5' primer that contains a T7 polymerase binding site, a sequence that allows translation initiation of mRNA, an in frame sequence coding for a FLAG epitope marker (Applicant's SEQ ID NO:7), and a 5' hybridization sequence "of sufficient length to allow the oligomer to hybridize to the non coding strand of the test sequence present in the genomic DNA or cDNA sample and to act as a primer for PCR. Usually 20 bases are enough" (see column 3, lines 59-67 and

column 4, lines 1-26 as well as Garvin et al's SEQ ID NO:2). Garvin et al also teach such method comprising the use of a 3' primer which comprises an inverse complement of sequence encoding a peptide tag and a sequence that hybridizes to a sequence at or adjacent to the 3' end of the coding strand of the test sequence. Most importantly, Garvin et al teach that in one embodiment the method comprises the use of one tag in the 5' primer and a different tag in the 3' primer and that this allows for a preferred two-step purification process wherein a ligand for either the N-terminal tag or C-terminal tag is used in the first step, and a ligand for the other peptide tag is used in the second purification step (see column 6, lines 5-36). Garvin et al further teach that this two step process will discriminate between polypeptides that result from transcription/translation of the entire amplified DNA template and those containing premature stop codons and/or those which result from internal translation initiation (ibid). Garvin et al also teach the use of mass spectrometry to determine the mass/identification of the translated protein (see, e.g., the Abstract). However, Garvin et al do not teach two epitope markers for the first primer.

Knop et al (Yeast 15: 963-972, 1999, specifically p. 968 and Table 1) teach epitope tagging of proteins. A primer (first primer) can comprise two or more epitope tags (first and second epitope markers), which are different. Therefore, the other, different epitope marker on the second primer as taught by Garvin et al would constitute the "third epitope marker". Knop et al teach that a primer with two tags is useful because it allows for affinity purification via two steps.

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the teachings of Little et al with regard to the reaction mixture required to detect mutations in the APC gene with the teachings of Gavin et al with regard to the methods/reaction mixtures required to detect mutations in, e.g., the BRCA1 and BRCA2 genes with the teachings of Knop et al with regard to a primer comprising two epitope tags because both Little et al and Gavin et al teach the use of PCR amplification and *in vitro* translation of epitope-tagged protein products in order to determine whether protein-altering mutations are present in a gene.

One of ordinary skill in the art would have been motivated to combine the teachings of Little et al with those of Garvin et al and Knop et al because Garvin et al and Knop et al teach that the use of a second tag, different from the first, would allow for a two step purification process that could distinguish between full length protein products and those which were truncated and/or those which were the product of internal translation initiation. This is desirable because both Gavin et al and Little et al teach that the mass of the protein could be easily assessed via mass spectrometry in order to detect protein-altering mutations.

Based upon the teachings of the cited references, the high skill of one of ordinary skill in the art, and absent evidence to the contrary, there would have been a reasonable expectation of success to result when combining the teachings of Little et al with those of Garvin et al and Knop et al.

Claims 1, 9 and 11-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Little et al (cited above) in view of Garvin et al (cited above) and in view of Knop et al (cited above) as applied to claims 1, 9 and 11-12 above, and further in view of Elion et al (*Current Protocols in Molecular Biology*, Unit 3.17, pages 3.17.1-3.17.10, 1993).

Little et al, Garvin et al and Knop et al teach all of the limitations as described above. However, they do not teach such a reaction mixture wherein the second region of complementarity is greater than 15 bases in length.

Elion teaches critical parameters for PCR reactions for constructing recombinant DNA molecules. Elion teaches that with regard to the design of primers, sequences with 16 to 20 nucleotides of homology to the target sequence should be chosen (see page 3.17.4, 1<sup>st</sup> column, 2<sup>nd</sup> full paragraph). Elion also teaches that "longer oligonucleotide of ~25 nucleotides should be used for AT-rich regions" and that in instances where genomic DNA is used as the source of target DNA, "the oligonucleotide primers should contain at least 20 nucleotides of homology to the target DNA to ensure that they anneal specifically" (ibid).

It would have been obvious for one of ordinary skill in the art to combine the teachings of Little et al in view of Garvin et al with those of Elion because Little et al in view of Garvin et al teach a PCR reaction mixture for the amplification of genes to detect protein-affecting mutations and Elion teaches well-established protocols with regard to parameters involved in PCR reactions, including primer design.



Given the teachings provided by Little et al and Garvin et al regarding the use of PCR reaction mixtures to detect protein-altering mutations, one of ordinary skill in the art interested in practicing the inventions of Little et al and Garvin et al would have been motivated to turn to the teachings of Elion et al for technical assistance in the design of primers for successful practice.

Based upon the teachings of the cited references, the high skill of one of ordinary skill in the art, the well-established PCR protocols established by the time of Applicant's filing, and absent evidence to the contrary, there would have been a reasonable expectation of success to result when combining the teachings of Little et al in view of Garvin et al with those of Elion.

***Allowable Subject Matter***

No claims are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHELE K. JOIKE whose telephone number is (571)272-5915. The examiner can normally be reached on M-F, 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (703) 308-9010 ext 110. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NANCY VOGEL/  
Primary Examiner, Art Unit 1636

Michele K Joike  
Examiner  
Art Unit 1636

